The earnings call reflected strong business performance with record revenue growth, market leadership in key areas, and significant progress in its R&D pipeline. Despite some challenges in fixed duration regimens and impacts from Medicare Part D redesign, the company demonstrated resilience and strategic foresight.

Company Guidance -

Q3 2025

During the call, BeiGene provided a comprehensive update on their first quarter of fiscal year 2025, highlighting significant achievements across their business priorities. They reported a revenue of $1.1 billion, marking a 49% growth from Q1 2024, with BRUKINSA sales reaching $792 million, a 62% increase year-over-year. The company achieved GAAP profitability for the first time, driven by strong commercial performance across major markets, including a 60% growth in the U.S. and 75% in Europe. BeiGene's pipeline progress was underscored by the completion of enrollment in the Phase III CELESTIAL trial for sonrotoclax (sonro) in CLL, and plans to submit global filings in the second half of the year. Additionally, they highlighted the advancement of their BTK CDAC program, which has dosed over 600 patients and is moving into Phase III trials. The call also emphasized BeiGene's strategic investments in global manufacturing, including an $800 million facility in Hopewell, New Jersey, enhancing supply chain resilience. The company reaffirmed its full-year 2025 guidance, projecting revenue between $4.9 billion and $5.3 billion, with continued focus on expanding their oncology leadership and delivering value for patients and shareholders.

Record Revenue Growth

Global sales reached $1.1 billion, marking a 49% increase from Q1 2024. The U.S. market grew by 60%, with BRUKINSA driving significant growth.

BRUKINSA Market Leadership

BRUKINSA achieved market leader status in the U.S. BTK market with quarterly sales of $563 million, growing 60% year-over-year.

Global Expansion and Approvals

TEVIMBRA was approved for frontline ESCC in the U.S., and the company expanded its global reach with launches in over 80 markets.

GAAP Profitability

BeiGene achieved GAAP profitability for the first time, with a strong increase in net income and operating cash flow.

Progress in R&D Pipeline

Significant advancements in the hematology and solid tumor pipelines, including the initiation of new Phase III trials for BTK CDAC and other promising assets.

BeiGene Ltd (HK:6160) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HK:6160 Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	0.42 / -	-0.688	―	―	―
Aug 06, 2025	2025 (Q2)	0.21 / 0.55	-0.69	179.57% (+1.24)	―	―
May 07, 2025	2025 (Q1)	-0.35 / 0.00	-1.449	―	―	―
Mar 27, 2025	2024 (Q4)	-0.61 / -0.85	-2.124	59.75% (+1.27)	―	―
Nov 12, 2024	2024 (Q3)	-0.67 / -0.69	1.208	-156.95% (-1.90)	―	―
Aug 27, 2024	2024 (Q2)	-1.31 / -0.69	-2.185	68.42% (+1.50)	―	―
May 08, 2024	2024 (Q1)	-1.86 / -1.45	-2.016	28.13% (+0.57)	―	―
Feb 26, 2024	2023 (Q4)	-2.10 / -2.12	-2.589	17.96% (+0.46)	―	―
Nov 09, 2023	2023 (Q3)	-2.04 / 1.21	-3.254	137.12% (+4.46)	―	―
Aug 25, 2023	2023 (Q2)	-2.02 / -2.19	-3.357	34.91% (+1.17)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HK:6160 Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	HK$186.30	HK$182.70	-1.93%
May 07, 2025	HK$153.20	HK$141.00	-7.96%
Mar 27, 2025	HK$151.70	HK$159.60	+5.21%
Nov 12, 2024	HK$125.20	HK$121.80	-2.72%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BeiGene Ltd (HK:6160) report earnings?

BeiGene Ltd (HK:6160) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is BeiGene Ltd (HK:6160) earnings time?

BeiGene Ltd (HK:6160) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of BeiGene Ltd stock?

The P/E ratio of BeiGene Ltd is N/A.

What is HK:6160 EPS forecast?

HK:6160 EPS forecast for the fiscal quarter 2025 (Q3) is 0.42.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing